Cargando…
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
BACKGROUND: Tumor infiltrating lymphocytes (TILs) reflect adaptive antitumor immune responses in cancer and are generally associated with favorable prognosis. However, the relationships between TILs subsets and their spatial arrangement with clinical benefit from immune checkpoint inhibitors (ICI) i...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161072/ https://www.ncbi.nlm.nih.gov/pubmed/35649657 http://dx.doi.org/10.1136/jitc-2021-004440 |
_version_ | 1784719409040850944 |
---|---|
author | Lopez de Rodas, Miguel Nagineni, Venkata Ravi, Arvind Datar, Ila J Mino-Kenudson, Mari Corredor, German Barrera, Cristian Behlman, Lindsey Rimm, David L Herbst, Roy S Madabhushi, Anant Riess, Jonathan W Velcheti, Vamsidhar Hellmann, Matthew D Gainor, Justin Schalper, Kurt A |
author_facet | Lopez de Rodas, Miguel Nagineni, Venkata Ravi, Arvind Datar, Ila J Mino-Kenudson, Mari Corredor, German Barrera, Cristian Behlman, Lindsey Rimm, David L Herbst, Roy S Madabhushi, Anant Riess, Jonathan W Velcheti, Vamsidhar Hellmann, Matthew D Gainor, Justin Schalper, Kurt A |
author_sort | Lopez de Rodas, Miguel |
collection | PubMed |
description | BACKGROUND: Tumor infiltrating lymphocytes (TILs) reflect adaptive antitumor immune responses in cancer and are generally associated with favorable prognosis. However, the relationships between TILs subsets and their spatial arrangement with clinical benefit from immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) remains less explored. METHODS: We used multiplexed quantitative immunofluorescence panels to determine the association of major TILs subpopulations, CD8(+) cytotoxic T cells, CD4(+) helper T cells and CD20(+) B cells, and T cell exhaustion markers, programmed cell death protein-1 (PD-1), lymphocyte-activation gene 3 (LAG-3) and T cell immunoglobulin mucin-3 (TIM-3) with outcomes in a multi-institutional cohort of baseline tumor samples from 179 patients with NSCLC treated with ICI. The analysis of full-face tumor biopsies including numerous fields of view allowed a detailed spatial analysis and assessment of tumor immune heterogeneity using a multiparametric quadratic entropy metric (Rao’s Q Index (RQI)). RESULTS: TILs were preferentially located in the stromal tissue areas surrounding tumor-cell nests and CD8(+) T cells were the most abundant subset. Higher density of stromal CD8(+) cytotoxic T cells was significantly associated with longer survival, and this effect was more prominent in programmed death ligand-1 (PD-L1) positive cases. The role of baseline T cell infiltration to stratify PD-L1 expressing cases was confirmed measuring the T cell receptor-burden in an independent NSCLC cohort studied with whole-exome DNA sequencing. High levels of LAG-3 on T cells or elevated RQI heterogeneity index were associated with worse survival in the cohort. CONCLUSION: Baseline T cell density and T cell exhaustion marker expression can stratify outcomes in PD-L1 positive patients with NSCLC treated with ICI. Spatial immune heterogeneity can be measured using the RQI and is associated with survival in NSCLC. |
format | Online Article Text |
id | pubmed-9161072 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-91610722022-06-16 Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer Lopez de Rodas, Miguel Nagineni, Venkata Ravi, Arvind Datar, Ila J Mino-Kenudson, Mari Corredor, German Barrera, Cristian Behlman, Lindsey Rimm, David L Herbst, Roy S Madabhushi, Anant Riess, Jonathan W Velcheti, Vamsidhar Hellmann, Matthew D Gainor, Justin Schalper, Kurt A J Immunother Cancer Immunotherapy Biomarkers BACKGROUND: Tumor infiltrating lymphocytes (TILs) reflect adaptive antitumor immune responses in cancer and are generally associated with favorable prognosis. However, the relationships between TILs subsets and their spatial arrangement with clinical benefit from immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) remains less explored. METHODS: We used multiplexed quantitative immunofluorescence panels to determine the association of major TILs subpopulations, CD8(+) cytotoxic T cells, CD4(+) helper T cells and CD20(+) B cells, and T cell exhaustion markers, programmed cell death protein-1 (PD-1), lymphocyte-activation gene 3 (LAG-3) and T cell immunoglobulin mucin-3 (TIM-3) with outcomes in a multi-institutional cohort of baseline tumor samples from 179 patients with NSCLC treated with ICI. The analysis of full-face tumor biopsies including numerous fields of view allowed a detailed spatial analysis and assessment of tumor immune heterogeneity using a multiparametric quadratic entropy metric (Rao’s Q Index (RQI)). RESULTS: TILs were preferentially located in the stromal tissue areas surrounding tumor-cell nests and CD8(+) T cells were the most abundant subset. Higher density of stromal CD8(+) cytotoxic T cells was significantly associated with longer survival, and this effect was more prominent in programmed death ligand-1 (PD-L1) positive cases. The role of baseline T cell infiltration to stratify PD-L1 expressing cases was confirmed measuring the T cell receptor-burden in an independent NSCLC cohort studied with whole-exome DNA sequencing. High levels of LAG-3 on T cells or elevated RQI heterogeneity index were associated with worse survival in the cohort. CONCLUSION: Baseline T cell density and T cell exhaustion marker expression can stratify outcomes in PD-L1 positive patients with NSCLC treated with ICI. Spatial immune heterogeneity can be measured using the RQI and is associated with survival in NSCLC. BMJ Publishing Group 2022-06-01 /pmc/articles/PMC9161072/ /pubmed/35649657 http://dx.doi.org/10.1136/jitc-2021-004440 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Immunotherapy Biomarkers Lopez de Rodas, Miguel Nagineni, Venkata Ravi, Arvind Datar, Ila J Mino-Kenudson, Mari Corredor, German Barrera, Cristian Behlman, Lindsey Rimm, David L Herbst, Roy S Madabhushi, Anant Riess, Jonathan W Velcheti, Vamsidhar Hellmann, Matthew D Gainor, Justin Schalper, Kurt A Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer |
title | Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer |
title_full | Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer |
title_fullStr | Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer |
title_full_unstemmed | Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer |
title_short | Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer |
title_sort | role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to pd-1 axis blockers in non-small cell lung cancer |
topic | Immunotherapy Biomarkers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161072/ https://www.ncbi.nlm.nih.gov/pubmed/35649657 http://dx.doi.org/10.1136/jitc-2021-004440 |
work_keys_str_mv | AT lopezderodasmiguel roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer AT naginenivenkata roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer AT raviarvind roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer AT datarilaj roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer AT minokenudsonmari roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer AT corredorgerman roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer AT barreracristian roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer AT behlmanlindsey roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer AT rimmdavidl roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer AT herbstroys roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer AT madabhushianant roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer AT riessjonathanw roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer AT velchetivamsidhar roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer AT hellmannmatthewd roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer AT gainorjustin roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer AT schalperkurta roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer |